1-20 of 22
Ursula Vehling-Kaiser
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Florian Simon, Rudy Ligtvoet, Moritz Fürstenau, Petra Langerbeins, Anna Maria Fink, Julia Von Tresckow, Paula Cramer, Christian Bjørn Poulsen, Thomas Illmer, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Liliya Sivcheva, Javier Loscertales, Kathleen Jentsch-Ullrich, Holger F. Hebart, Mark-David Levin, Caspar Da Cunha-Bang, Nadine Kutsch, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Sandra Robrecht, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Michael Hallek, Barbara F. Eichhorst, Othman Al-Sawaf
Journal: Blood
Blood (2024) 144 (Supplement 1): 6799.
https://doi.org/10.1182/blood-2024-203673
Published: 2024
Journal Articles

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn, Thomas Noesslinger, Julia Von Tresckow, Ruediger Liersch, Tobias Gaska, Kathleen Jentsch-Ullrich, Michael Gärtner, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Ursula Vehling-Kaiser, Matthias Ritgen, Christian Spoer, Michael J. Eckart, Thomas Decker, Geothy Chakupurakal, Björn Schöttker, Jens Kisro, Janina Stumpf, Eugen Tausch, Stephan Stilgenbauer, Karl-Anton Kreuzer, Sandra Robrecht, Anna Maria Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael Hallek, Barbara F. Eichhorst
Journal: Blood
Blood (2024) 144 (Supplement 1): 4618.
https://doi.org/10.1182/blood-2024-200848
Published: 2024
Journal Articles

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Ellinor Goergen, Sandra Robrecht, Adam Giza, Can Zhang, Pascal Nieper, Florian Simon, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Nadine Kutsch, Anna Maria Fink, Ursula Vehling-Kaiser, Lothar Müller, Michael J. Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Beate Stauch, Clemens-Martin Wendtner, Eugen Tausch, Christof Schneider, Kirsten Fischer, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael Hallek, Petra Langerbeins
Journal: Blood
Blood (2024) 144 (Supplement 1): 1859.
https://doi.org/10.1182/blood-2024-200903
Published: 2024
Journal Articles

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Emelie Curovic Rotbain, Laura Eurelings, Sandra Robrecht, Julia Von Tresckow, Adam Giza, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Christof Schneider, Thomas Noesslinger, Martin Andres, Adrian Schmidt, Elisabeth Vandenberghe, Lev Shvidel, Christian Bjørn Poulsen, Henrik Frederiksen, Caspar Da Cunha-Bang, Kourosh Lotfi, Rogier Mous, Martine E.D. Chamuleau, Ka Lung Wu, Margriet Oosterveld, Jesus Duque-Afonso, Christian Bogner, Thomas Wolff, Johannes Schetelig, Ursula Vehling-Kaiser, Christoph van Roye, Nadine Kutsch, Anna Maria Fink, Kirsten Fischer, Emily Holmes, Matthias Ritgen, Eugen Tausch, Stephan Stilgenbauer, Michael J. Hallek, Arnon P. Kater, Carsten Utoft Niemann, Mark-David Levin, Barbara F. Eichhorst
Journal: Blood
Blood (2024) 144 (Supplement 1): 3238.
https://doi.org/10.1182/blood-2024-198917
Published: 2024
Journal Articles

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna Maria Fink, Eugen Tausch, Christof Schneider, Sebastian Böttcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia Von Tresckow, Ursula Vehling-Kaiser, Clemens-Martin Wendtner, Kirsten Fischer, Karl Anton Kreuzer, Stephan Stilgenbauer, Philipp Bernhard Staber, Carsten Utoft Niemann, Michael Hallek, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 204.
https://doi.org/10.1182/blood-2023-188705
Published: 2023
Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 199.
https://doi.org/10.1182/blood-2023-180558
Published: 2023
Journal Articles

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Furstenau, Valentin Goede, Julia Von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens-Martin Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas Illmer, Michael Gregor, Philipp Bernhard Staber, Stephan Stilgenbauer, Carsten Utoft Niemann, Arnon P. Kater, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2023) 142 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2023-178597
Published: 2023
Journal Articles

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Armin Riecke, Christof Schneider, Billy Jebaraj, Hassan Jumaa, Marc Young, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer, Eugen Tausch
Journal: Blood
Blood (2023) 142 (Supplement 1): 1903.
https://doi.org/10.1182/blood-2023-179767
Published: 2023
Journal Articles

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Eva Hoster, Marie-Helene Delfau, Elizabeth A. Macintyre, Linmiao Jiang, Stephan Stilgenbauer, Ursula Vehling-Kaiser, Gilles Salles, Catherine Thieblemont, Hervé Tilly, Lothar Kanz, Pierre Feugier, Kai Huebel, Christian Schmidt, Vincent Ribrag, Hanneke Kluin-Nelemans, Martin Dreyling, Christiane Pott
Journal: Blood
Blood (2022) 140 (Supplement 1): 1304–1306.
https://doi.org/10.1182/blood-2022-159932
Published: 2022
Journal Articles

Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

Nadine Kutsch, Anna Maria Fink, Anno Federhen, Adam Giza, Sandra Robrecht, Janina Stumpf, Andrea Stoltefuß, Ursula Vehling-Kaiser, Michael Koenigsmann, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Thomas Illmer, Rudolf Schlag, Steffen Dörfel, Tobias Gaska, Michael G. Kiehl, Kirsten Fischer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 140 (Supplement 1): 9879–9881.
https://doi.org/10.1182/blood-2022-169956
Published: 2022
Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Clinical Trials & Observations
Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Müller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 139 (2): 177–187.
https://doi.org/10.1182/blood.2021010845
Published: 2022
Includes: Supplemental data
Journal Articles

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Paula Cramer, Carmen D. Herling, MD PhD, Julia Von Tresckow, MD, Elisabeth Lange, MD, Sebastian Böttcher, MD PhD, Michael G. Kiehl, MD PhD, Martin Dreyling, MD, Ulrich Jaeger, Michael Gregor, MD, Ursula Vehling-Kaiser, MD, Matthias Ritgen, MD, Jan Dürig, MD, Eugen Tausch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Valentin Goede, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Petra Langerbeins, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139242
Published: 2020
Journal Articles

Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)

Nadine Kutsch, MD, Sebastian Böttcher, MD PhD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, MD, Michael G Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, MD, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Ilske Oschlies, MD, Marco Herling, MD PhD, Kirsten Fischer, MD, Hartmut Döhner, MD, Michael Kneba, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD PhD, Anna Maria Fink, MD, Michael Hallek, MD, Wolfram Klapper, MD, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3021.
https://doi.org/10.1182/blood.V130.Suppl_1.3021.3021
Published: 2017
Journal Articles

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

Eva Hoster, Hanneke Kluin-Nelemans, MD PhD, Olivier Hermine, MD PhD, Jan Walewski, MD PhD, Marek Trneny, MD, Christian H. Geisler, MD PhD, Stephan Stilgenbauer, MD PhD, Catherine Thieblemont, MD PhD, Ursula Vehling-Kaiser, MD, Jeanette K. Doorduijn, MD PhD, Lionel Karlin, MD, Roswitha Forstpointner, MD, Herve Tilly, Michal Szymczyk, MD, Vincent Ribrag, MD, Marc Andre, MD, Wolfram Klapper, MD, Wolfgang Hiddemann, Michael Unterhalt, MD PhD, Martin Dreyling, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 153.
https://doi.org/10.1182/blood.V130.Suppl_1.153.153
Published: 2017
Journal Articles

Bendamustine Followed By Ofatumumab and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BIO Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Julia von Tresckow, MD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Othman Al-Sawaf, MD, Petra Langerbeins, MD, Werner Heinz, MD, Ursula Vehling-Kaiser, MD, Jan Dürig, MD, Eugen Tausch, MD, Manfred Hensel, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Karl-Anton Kreuzer, MD, Sebastian Böttcher, MD PhD, Matthias Ritgen, Michael Kneba, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD PhD, Barbara F. Eichhorst, MD, Michael J. Hallek, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 494.
https://doi.org/10.1182/blood.V130.Suppl_1.494.494
Published: 2017
Journal Articles

Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara F. Eichhorst, MD, Jasmin Bahlo, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, Prof., Michael G Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, Torben Plesner, MD, Marco Herling, MD PhD, Kirsten Fischer, Hartmut Döhner, MD, Michael Kneba, Clemens Wendtner, MD, Wolfram Klapper, MD, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 4382.
https://doi.org/10.1182/blood.V128.22.4382.4382
Published: 2016
Journal Articles

Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

Petra Langerbeins, MD, Jasmin Bahlo, Christina Rhein, Paula Cramer, MD, Anna-Maria Fink, MD, Natali Pflug, MD, Julia von Tresckow, MD, Stephan Stilgenbauer, MD, Karl-Anton Kreuzer, Michael J. Eckart, MD, Ursula Vehling-Kaiser, MD, Rudolf Schlag, MD, Christina Balser, MD, Lothar Müller, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2015) 126 (23): 2934.
https://doi.org/10.1182/blood.V126.23.2934.2934
Published: 2015
Journal Articles

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, MD, Anna Maria Fink, MD, Raymonde Busch, Gabor Kovacs, MD, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, Prof. Dr., Michael G Kiehl, MD, Martin Soekler, MD, Rudolf Schlag, Ursula Vehling-Kaiser, MD, Georg R.A. Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Marek Trneny, MD, Kirsten Fischer, Hartmut Döhner, MD, Michael Kneba, MD PhD, Clemens-Martin Wendtner, MD, Wolfram Klapper, MD, Karl Anton Kreuzer, Prof. Dr. MD, Stephan Stilgenbauer, MD PhD, Sebastian Böttcher, MD, Michael Hallek, MD
Journal: Blood
Blood (2014) 124 (21): 19.
https://doi.org/10.1182/blood.V124.21.19.19
Published: 2014
Journal Articles

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

Manuela A. Bergmann, MD, Raymonde Busch, PhD, Barbara Eichhorst, MD, Andreas Buehler, MD, Norbert Fischer, MD, Michael J Eckart, MD, Ursula Vehling-Kaiser, MD, Ulrich Jäger, MD, Georg Hopfinger, MD, Clemens Wendtner, MD, Kirsten Fischer, MD, Bertold Emmerich, MD, Hartmut Döhner, MD, Michael Hallek, M.D. Ph.D., Stephan Stilgenbauer, MD
Journal: Blood
Blood (2013) 122 (21): 4127.
https://doi.org/10.1182/blood.V122.21.4127.4127
Published: 2013
Journal Articles

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial

Carmen D Schweighofer, MD, Florence Cymbalista, MD, Carolin Müller, MD, Raymonde Busch, PhD, Raphael Porcher, PhD, Petra Langerbeins, MD, Bruno Cazin, MD, Anna-Maria Fink, MD, Brigitte Dreyfus, MD, Stefan Ibach, Stéphane Leprêtre, MD, Kirsten Fischer, MD, Ursula Vehling-Kaiser, MD, Barbara Eichhorst, MD, Manuela A. Bergmann, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Veronique Leblond, MD, Michael Hallek, MD, Vincent Levy, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 524.
https://doi.org/10.1182/blood.V122.21.524.524
Published: 2013